Related Experiment Video
Updated: May 20, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Remission in psoriatic arthritis.
Anna Caperon1, Philip S Helliwell
1Section of Musculoskeletal Disease, University of Leeds, Harehills Lane, Leeds, United Kingdom.
The Journal of Rheumatology. Supplement
|July 4, 2012
Summary
Psoriatic arthritis (PsA) outcome measurement is complex. While articular measures exist, emerging composite tools for low disease states require further validation for effective treatment strategies.
Area of Science:
- Rheumatology
- Clinical Trial Methodology
- Patient-Reported Outcomes
Background:
- Psoriatic arthritis (PsA) presents multifaceted challenges for outcome measurement.
- Current remission definitions in PsA predominantly focus on articular symptoms.
- There is a need for comprehensive outcome measures in PsA research.
Purpose of the Study:
- To review existing measures for defining remission in psoriatic arthritis.
- To explore the emergence and utility of composite measures for low disease states in PsA.
- To identify future research directions for optimizing PsA treatment strategies.
Main Methods:
- Literature review of existing PsA outcome measures.
- Analysis of current trends in composite disease activity indices.
- Discussion of the implications of achieving low disease states in PsA.
Main Results:
- Existing PsA remission measures are largely articular-focused.
- Composite measures for assessing disease activity and low disease states are emerging.
- Further research is needed to validate these new measures and their clinical implications.
Conclusions:
- Current psoriatic arthritis outcome measures require enhancement beyond articular symptoms.
- Emerging composite measures offer promise for a more holistic assessment of PsA.
- Future work should focus on validating these measures and developing cost-effective strategies to achieve low disease states in PsA.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...